ABSTRACT: Background: Cancer is a health problem in the world and in Indonesia, in addition to the high incidence and risk of death from cancer, the high cost of cancer treatment is also a factor problems. Lung cancer is the cancer cases are most common in the world. The number of treatment options for patients with advanced non-small cell lung cancer makes economic factors be one consideration in determining the optimal treatment for patients with side effects and costs to a minimum. Objective: This study aimed to determine the total cost of treatment of patients with advanced NSCLC who received chemotherapy in the Dharmais Cancer Hospital Jakarta. Methods: The study is descriptive quantitative with cross sectional study design. Data were collected retrospectively from patient�s medical records and Hospital Information Systems. Results: There were 102 patients included in the study, 79 (77.5 %) patients diagnosed at stage IV and 19 (18.6 %) of patients in stage IIIB. Sources of financing the patient is at most National Health Insurance as many as 34 patients (33.3 %), and 26 patients (25.5 %) who pay by themselves all the costs of treatment for hospitalized. The largest cost component of the overall cost of treatment is a chemotherapy drug costs, a percentage of the overall total cost of 34.14 % in patients with stage IIIB and 28.48 % in stage IV patients. Chemotherapy regimens with the biggest cost is the combination of pemetrexed and cisplatin. Conclusion: There is no significant difference between the treatment costs of patients diagnosed with stage IIIB and IV, as well as between male and female patients. Component of the overall cost of treating patients, the cost of drugs and medical devices is the largest cost component of the total cost, including the cost of chemotherapy drugs. There is no significant effect between patient factors and chemotherapy against treatment costs of NSCLC patients
